China has taken a significant step in the global race to commercialise brain-computer interface (BCI) technology, with researchers describing it as the world’s first commercially available implantable brain chip, ahead of Elon Musk’s Neuralink.
The device, known as NEO, was developed by Shanghai-based Neuracle Medical Technology and has received regulatory approval for use in patients with spinal cord injuries and paralysis following successful clinical trials.
The approval makes China the first country to commercially authorise an invasive brain-computer interface for medical use, which marks a milestone in neurotechnology.
The development puts China ahead of Neuralink in commercial deployment. While Neuralink has successfully implanted its devices in a limited number of human trial participants and continues clinical testing in the United States, it has not yet received approval for broad commercial use.
How China’s NEO Differs from Neuralink
NEO uses electrodes positioned on the brain’s protective outer membrane (the dura mater),
This post was originally published on this site.
